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Targeted therapies directed against cell cycle regulators have been difficult to translate into the clinic.
In this issue of Cancer Cell, Choi et al. and Sawai et al. rekindle the therapeutic value of inhibiting specific
cyclin-dependent kinase complexes by demonstrating their requirements in the maintenance of breast
tumors and leukemias.‘‘The real problem is to understand
why cancer cells grow when their
normal counterparts would not.’’
(Hunt, 2008)
Tumor cells invariably display defects in
the machinery that controls the cell divi-
sion cycle. Yet, whether the cell cycle is
a useful therapeutic target is still being
intensely debated mostly due to the
essential role of this process in tissue
homeostasis and the difficulties of finding
a therapeutic window (Malumbres and
Barbacid, 2009). Progression through
the cell cycle is driven by several protein
kinases, including cyclin-dependent
kinases (CDKs). Molecular analysis of
tumor cells has provided strong evidence
that the activity of these kinases is de-
regulated in human tumors suggesting
their potential therapeutic use. However,
the clinical benefit of the first generation
of CDK inhibitors has been limited due to
toxicity and lack of specificity, possibly
derived from the critical function of
CDKs in DNA replication and chromo-
some segregation.
The pioneering work by P. Sicinski’s
group in 2001 (Yu et al., 2001) showed
that a specific interphase cyclin, cyclin
D1, was required for RAS- and HER2-
induced mammary tumors, but was
dispensable for WNT- or MYC-induced
mammary tumors. This work showed for
the first time that the therapeutic value
of a cell cycle regulator may be cell-type
specific and dependent on specific onco-
genic alterations. These studies were per-
formed using germline cyclin D1 knockout
mice, which raised some important
questions at that time. Since cyclin D1
knockout mice displayed minor defects
in mammary gland development, it was
argued that the effect observed could be
due to special requirements for cyclin D1in the cell of origin of these tumors. Two
studies in 2006 suggested that this was
not the case, as a similar therapeutic
benefit was observed using CDK4-defi-
cient mice or knockin mice expressing
a mutant cyclin D1, which does not bind
CDKs but maintains other CDK-indepen-
dent functions (Landis et al., 2006; Yu
et al., 2006). None of these models
displayed defects in mammary gland
development; yet, they were resistant to
HER2-induced mammary gland carci-
nomas. In addition, these studies sug-
gested that CDK4, one of the kinase
partners of cyclin D1, was the critical
enzymatic activity to be targeted in
HER2-positive mammary gland carci-
nomas. Subsequent studies by Barbacid
and colleagues (Puyol et al., 2010)
showed that CDK4, but not CDK2 or
CDK6, was critical for the development
of K-RAS-induced lung tumors, whereas
lack of this interphase kinase did not
affect the development of lungs in germ-
line knockout mice.
Because the genetic modification was
present since conception, the remaining
question was whether the acute inhibition
of cyclin D1-CDK complexes would be
effective in already developed breast
tumors. A new study in this issue of
Cancer Cell by Choi et al. (2012) now
shows that conditional genetic ablation
of cyclin D1 in adult mice that bear tumors
inhibits the growth of HER2-positive
mammary carcinomas. A similar effect is
obtained using a small-molecule inhibitor
of CDK4/6 (PD 0332991) currently being
studied in clinical trials. Importantly, this
effect is not accompanied by toxicities
associated with the acute inhibition of cy-
clin D1-CDK complexes in adult individ-
uals (Puyol et al., 2010; Choi et al., 2012;
Sawai et al., 2012), suggesting that side-
effects of such treatments will be minimal.Cancer Cell 22Based on the previous results, cyclin
D1-CDK4 complexes seem to be critical
targets in the proliferation of epithelial
tumors, at least breast and lung carci-
nomas (Figure 1). What about other
interphase CDK complexes? Previous
studies established a critical role for
cyclin D3 and, at least partially, CDK6
in lymphocytes and in the development
of T cell leukemias (Hu et al., 2009;
Sicinska et al., 2003). The relevance of
these findings in cancer therapy has
now been addressed using conditional
knockouts or acute treatments with
kinase inhibitors. Genetic ablation of
cyclin D3 or inhibition of CDK4/6
complexes in Notch1-induced T cell
acute lymphoblastic leukemia (T-ALL)
results in tumor regression without
causing major abnormalities in other
tissues (Choi et al., 2012; Sawai
et al., 2012; in this issue of Cancer Cell).
Importantly, the response of leukemic
cells to these treatments is dramatically
different from that of epithelial cells.
Both lung and breast cancer cells display
characteristics of cell cycle arrest and
senescence after genetic ablation or
chemical inhibition of cyclin D1-CDK4
complexes (Choi et al., 2012; Puyol
et al., 2010). Similar treatments, however,
result in apoptotic cell death in mouse
and human leukemic cells (Choi et al.,
2012; Sawai et al., 2012). This response
seems to be associated with the
finding that Notch1-induced tumors
display high levels of cyclin D2/D3 and
cyclin D3-CDK6 complexes in agree-
ment with the modulation of cyclin
D3 expression by the Notch1 pathway
(Choi et al., 2012; Joshi et al., 2009).
In fact, Notch1-negative T-ALLs or
other types of leukemic cells did not
undergo apoptosis following CDK4/6
inhibition (Choi et al., 2012). Whether the, October 16, 2012 ª2012 Elsevier Inc. 419
Figure 1. An Initial Road Map for the Treatment of Human
Malignancies with Specific CDK4/6 Inhibitors
Since the small-molecule inhibitor PD 0332991 inhibits both CDK4 and
CDK6 complexes, the participation of CDK4 in human leukemias cannot
be discarded at this time. Similarly, it is not clear which specific cyclins
activate CDK4 in lung tumors, although this information is likely to be dis-
pensable for the selection of small-molecule kinase inhibitors. Further
research will be necessary to evaluate the relevance of specific cyclin-CDK
complexes in similar pathologies induced by other oncogenes (e.g., mammary
gland or lung tumors without activation of the RAS pathway) or in other
tumor types.
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provided by the activation of
Notch1 or the specific
inhibition of cyclin D3-(and
possibly CDK6) complexes
is not clear at present. Inter-
estingly, cyclin D2 cannot
compensate for the lack of
cyclin D3 when expressed
from the Ccnd3 locus sug-
gesting intrinsic differences
in the function of these two
proteins (Sawai et al., 2012).




may be considered a new
avenue of high interest in
the therapeutic evaluation of
these cell cycle regulators.
It is been a long road—20
years—since the initial gene-
ration of genetically-engi-
neered mice with cell cycle
mutations. The discovery
that individual interphase
cyclins or CDKs were dis-
pensable for the develop-ment and homeostasis of most tissues
was considered a demonstration of
the developmental plasticity of mamma-
lian tissues and raised doubts on the
usefulness of inhibiting these activities
in tumors (Malumbres and Barbacid,
2009). The recent studies in breast,
lung, and T-ALL make a strong case
for the identification of cellular contexts
in which the inhibition of specific cy-
clin-CDK complexes may have thera-
peutic value (Figure 1). Based on these
results, one could propose that many420 Cancer Cell 22, October 16, 2012 ª2012human tumors may be sensitive to
specific cyclin-CDK complexes, as long
as we identify the specific complexes
that mediate the response to specific
oncogenic pathways in each specific
cell type. A long road in which difficult
questions such as ‘‘why cancer cells
grow when their normal counterparts
would not’’ (Hunt, 2008) need to be
addressed in a cell-type- and onco-
gene-specific manner. Cancer patients
will undoubtedly benefit from these
studies.Elsevier Inc.REFERENCES
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